A 65-year-old man with newly diagnosed type 2 diabetes (HbA1c 9.5%) has established atherosclerotic cardiovascular disease (prior MI) and diabetic kidney disease (eGFR 40, albuminuria 500 mg/g). His cardiologist recommends an SGLT2 inhibitor, his nephrologist recommends a GLP-1 agonist, and the primary care physician suggests starting insulin for rapid control. Evaluate the optimal evidence-based treatment strategy.
Q2
A 48-year-old woman presents with a 3 cm thyroid nodule discovered incidentally. TSH is 2.5 mIU/L (normal). FNA biopsy shows Bethesda Category IV (follicular neoplasm). Molecular testing shows a RAS mutation. She is anxious about cancer and requests total thyroidectomy. Her surgeon suggests thyroid lobectomy. Synthesize the best management approach considering oncologic outcomes, quality of life, and patient preferences.
Q3
A 32-year-old woman with type 1 diabetes for 20 years presents with recurrent severe hypoglycemia despite optimal insulin management and continuous glucose monitoring. She has hypoglycemia unawareness and two recent episodes requiring emergency glucagon. HbA1c is 6.8%. She has gastroparesis and proliferative retinopathy but preserved kidney function (eGFR >60). Her endocrinologist is considering islet cell transplantation. Evaluate the appropriateness of this intervention.
Q4
A 42-year-old woman undergoes total thyroidectomy for papillary thyroid cancer. Postoperatively, she develops perioral numbness and carpopedal spasm. Calcium is 6.8 mg/dL, phosphate 5.8 mg/dL, PTH <10 pg/mL, and magnesium 1.2 mg/dL. She is given IV calcium gluconate with minimal improvement. Analysis of her labs reveals which underlying mechanism preventing response to calcium supplementation?
Q5
A 70-year-old man with type 2 diabetes, hypertension, and stage 4 CKD (eGFR 25 mL/min/1.73m²) presents with HbA1c of 9.2%. Current medications include metformin 1000 mg twice daily, lisinopril, and atorvastatin. He experienced severe hypoglycemia twice in the past month with glucose readings in the 40s mg/dL. Analyze the most likely cause of his hypoglycemia.
Q6
A 38-year-old woman presents with fatigue, weight gain, and cold intolerance. Labs show TSH 45 mIU/L, free T4 0.4 ng/dL, and positive anti-thyroid peroxidase antibodies. She is started on levothyroxine 100 mcg daily. Four weeks later, she reports palpitations, anxiety, and insomnia. Repeat TSH is 35 mIU/L and free T4 is 2.5 ng/dL. What best explains these findings?
Q7
A 55-year-old man with type 2 diabetes presents to the emergency department with confusion and lethargy. His glucose is 750 mg/dL, sodium 155 mEq/L, serum osmolality 380 mOsm/kg, pH 7.38, and bicarbonate 24 mEq/L. Urine ketones are negative. He is started on IV fluids and insulin. Six hours later, his glucose is 250 mg/dL but he remains confused. What is the most appropriate next step?
Q8
A 28-year-old pregnant woman at 10 weeks gestation presents with fatigue, palpitations, and tremor. TSH is <0.01 mIU/L, free T4 is 3.2 ng/dL, and β-hCG is markedly elevated at 400,000 mIU/mL. Thyroid stimulating immunoglobulins are negative. Ultrasound shows a molar pregnancy. What is the most appropriate management of her thyroid condition?
Q9
A 62-year-old man with type 2 diabetes mellitus on metformin and glipizide presents for routine follow-up. His HbA1c is 8.5% (goal <7%). He has a history of heart failure with reduced ejection fraction (EF 35%) and chronic kidney disease stage 3 (eGFR 45 mL/min/1.73m²). Which medication should be added to improve both glycemic control and cardiovascular outcomes?
Q10
A 45-year-old woman presents with heat intolerance, palpitations, and a 15-pound weight loss over 3 months. Physical examination reveals a diffusely enlarged, non-tender thyroid gland, fine tremor, and exophthalmos. TSH is 0.01 mIU/L (normal: 0.4-4.0), free T4 is 3.8 ng/dL (normal: 0.8-1.8), and thyroid-stimulating immunoglobulin is elevated. What is the most appropriate initial management?
Endocrinology (diabetes, thyroid disorders) US Medical PG Practice Questions and MCQs
Question 1: A 65-year-old man with newly diagnosed type 2 diabetes (HbA1c 9.5%) has established atherosclerotic cardiovascular disease (prior MI) and diabetic kidney disease (eGFR 40, albuminuria 500 mg/g). His cardiologist recommends an SGLT2 inhibitor, his nephrologist recommends a GLP-1 agonist, and the primary care physician suggests starting insulin for rapid control. Evaluate the optimal evidence-based treatment strategy.
A. SGLT2 inhibitor alone given kidney disease and heart failure benefits
B. Combination SGLT2 inhibitor and GLP-1 agonist with metformin (Correct Answer)
C. Insulin alone for rapid glycemic control given high HbA1c
D. Sequential therapy starting with SGLT2 inhibitor, then adding others
E. GLP-1 agonist alone given cardiovascular outcomes benefit
Explanation: ***Combination SGLT2 inhibitor and GLP-1 agonist with metformin***
- For patients with **type 2 diabetes** and established **atherosclerotic cardiovascular disease (ASCVD)** or **chronic kidney disease (CKD)**, current guidelines recommend both classes due to independent cardiovascular and renal protective benefits.
- **SGLT2 inhibitors** reduce **heart failure** hospitalization and slow **CKD progression (albuminuria)**, while **GLP-1 receptor agonists** significantly reduce **MACE** (major adverse cardiovascular events).
*Insulin alone for rapid glycemic control given high HbA1c*
- Although **insulin** effectively lowers high HbA1c, it is associated with **weight gain** and a higher risk of **hypoglycemia**.
- It lacks the specific **organ-protective** benefits (cardioprotection and renoprotection) demonstrated by **SGLT2 inhibitors** and **GLP-1 agonists**.
*SGLT2 inhibitor alone given kidney disease and heart failure benefits*
- While an **SGLT2 inhibitor** is crucial for this patient's **diabetic kidney disease** and **ASCVD**, using it as monotherapy may not provide sufficient **MACE** reduction compared to dual therapy.
- Given the high **HbA1c of 9.5%**, monotherapy is unlikely to achieve the glycemic targets required for this patient.
*GLP-1 agonist alone given cardiovascular outcomes benefit*
- **GLP-1 agonists** are excellent for **MACE** reduction, but they do not provide the same level of **hemodynamic protection** for the kidneys as **SGLT2 inhibitors**.
- Using a single agent would miss the synergistic **cardiorenal benefits** proven when these two classes are combined in high-risk patients.
*Sequential therapy starting with SGLT2 inhibitor, then adding others*
- **Sequential therapy** may delay reaching glycemic targets and postpone the initiation of life-saving **organ-protective** medications.
- Current **ADA/EASD guidelines** recommend early combination therapy in patients with established **ASCVD** and **CKD** to maximize survival and renal outcomes.
Question 2: A 48-year-old woman presents with a 3 cm thyroid nodule discovered incidentally. TSH is 2.5 mIU/L (normal). FNA biopsy shows Bethesda Category IV (follicular neoplasm). Molecular testing shows a RAS mutation. She is anxious about cancer and requests total thyroidectomy. Her surgeon suggests thyroid lobectomy. Synthesize the best management approach considering oncologic outcomes, quality of life, and patient preferences.
A. Thyroid lobectomy with completion thyroidectomy if cancer confirmed (Correct Answer)
B. Molecular testing panel expansion before deciding on surgery extent
C. Total thyroidectomy per patient preference to ensure cancer removal
D. Active surveillance with ultrasound every 6 months
E. Repeat FNA in 3 months to get definitive diagnosis first
Explanation: ***Thyroid lobectomy with completion thyroidectomy if cancer confirmed***
- For a **Bethesda IV** lesion (10-40% malignancy risk) and a 3 cm nodule, a **diagnostic lobectomy** is the standard recommended initial step to provide a definitive histological diagnosis.
- **Oncologic outcomes** (survival and recurrence) for thyroid lobectomy are equivalent to total thyroidectomy for differentiated thyroid cancers up to 4 cm without evidence of extrathyroidal extension or lymph node involvement.
*Total thyroidectomy per patient preference to ensure cancer removal*
- Performing a total thyroidectomy carries a higher risk of **permanent hypoparathyroidism** and **recurrent laryngeal nerve injury** compared to a lobectomy.
- While the patient is anxious, medical guidance emphasizes avoiding **overtreatment** and lifelong **levothyroxine dependence** when a less morbid procedure is oncologically sufficient.
*Repeat FNA in 3 months to get definitive diagnosis first*
- FNA cannot distinguish between **follicular adenoma** and **follicular carcinoma** because it cannot evaluate for **capsular or vascular invasion**.
- Repeating the FNA will not change the **Bethesda IV** status or provide the definitive diagnosis needed to rule out malignancy.
*Molecular testing panel expansion before deciding on surgery extent*
- While **RAS mutations** are common in follicular neoplasms, they have a low **positive predictive value (PPV)** for malignancy compared to BRAF V600E mutations.
- Expanding the panel is unnecessary here as the current findings already mandate **surgical excision** for diagnosis; further testing is unlikely to change the initial recommendation of lobectomy.
*Active surveillance with ultrasound every 6 months*
- **Active surveillance** is generally reserved for **Bethesda II** (benign) nodules or very low-risk **Bethesda VI** (papillary microcarcinomas) under strict protocols.
- A **3 cm follicular neoplasm** carries a significant risk of malignancy and potential for distal spread, making surveillance inappropriate without a histological diagnosis.
Question 3: A 32-year-old woman with type 1 diabetes for 20 years presents with recurrent severe hypoglycemia despite optimal insulin management and continuous glucose monitoring. She has hypoglycemia unawareness and two recent episodes requiring emergency glucagon. HbA1c is 6.8%. She has gastroparesis and proliferative retinopathy but preserved kidney function (eGFR >60). Her endocrinologist is considering islet cell transplantation. Evaluate the appropriateness of this intervention.
A. Inappropriate - preserved kidney function means she's not sick enough
B. Inappropriate - should undergo whole pancreas transplant instead
C. Inappropriate - HbA1c indicates adequate control without need for transplant
D. Appropriate - but should wait until kidney transplant is needed
E. Appropriate - meets criteria for hypoglycemia unawareness with complications (Correct Answer)
Explanation: ***Appropriate - meets criteria for hypoglycemia unawareness with complications***
- The primary indication for **islet cell transplantation** is type 1 diabetes with **hypoglycemia unawareness**, recurrent severe hypoglycemia, or extreme **glycemic lability** despite intensive therapy.
- This patient satisfies the criteria as she has had multiple episodes requiring emergency intervention and lacks the **autonomic warning symptoms** of falling blood glucose.
*Inappropriate - HbA1c indicates adequate control without need for transplant*
- A "good" **HbA1c** (6.8%) in this context is misleading, as it often reflects frequent **hypoglycemic episodes** rather than stable euglycemia.
- Clinical guidelines prioritize the **frequency of severe hypoglycemia** over the HbA1c value when determining eligibility for transplant.
*Inappropriate - preserved kidney function means she's not sick enough*
- **Preserved kidney function** does not preclude islet transplantation; in fact, it makes her a candidate for **islet transplantation alone (ITA)** rather than a combined procedure.
- The goal is to prevent further **microvascular complications** and life-threatening events, regardless of current renal status.
*Inappropriate - should undergo whole pancreas transplant instead*
- **Whole pancreas transplantation** is a major surgical procedure typically reserved for those who also require a **kidney transplant** due to the high operative risk.
- **Islet cell transplantation** is a minimally invasive alternative that is preferred for patients with preserved renal function who only need a restoration of **glucose sensing**.
*Appropriate - but should wait until kidney transplant is needed*
- Waiting for **renal failure** to occur is counter-productive, as the goal of metabolic stabilization is to protect against the progression of **diabetic nephropathy**.
- Isolated islet transplantation can be performed successfully to improve quality of life and **metabolic stability** before end-stage complications arise.
Question 4: A 42-year-old woman undergoes total thyroidectomy for papillary thyroid cancer. Postoperatively, she develops perioral numbness and carpopedal spasm. Calcium is 6.8 mg/dL, phosphate 5.8 mg/dL, PTH <10 pg/mL, and magnesium 1.2 mg/dL. She is given IV calcium gluconate with minimal improvement. Analysis of her labs reveals which underlying mechanism preventing response to calcium supplementation?
A. Hypomagnesemia causing PTH resistance and impaired secretion (Correct Answer)
B. Inadequate calcium dosing requiring higher infusion rate
C. Concurrent vitamin D deficiency requiring supplementation
D. Pseudohypoparathyroidism from PTH receptor mutation
E. Calcitonin excess from residual thyroid tissue
Explanation: ***Hypomagnesemia causing PTH resistance and impaired secretion***
- **Magnesium** is required for the adenylate cyclase-mediated release of **PTH**; therefore, severe **hypomagnesemia** (1.2 mg/dL) results in a state of functional hypoparathyroidism.
- Low magnesium also induces end-organ resistance to PTH, meaning IV calcium will not effectively resolve symptoms until the **magnesium deficiency** is corrected to allow proper PTH signaling.
*Concurrent vitamin D deficiency requiring supplementation*
- While **vitamin D deficiency** contributes to low calcium, it does not explain the very low **PTH** level (<10 pg/mL) seen in this patient.
- Hypocalcemia from vitamin D deficiency would typically cause a **compensatory rise** in PTH (secondary hyperparathyroidism), which is the opposite of this laboratory profile.
*Calcitonin excess from residual thyroid tissue*
- **Calcitonin** is produced by **parafollicular C-cells** and lowers calcium, but its effects are physiologically weak in adults and do not cause symptomatic carpopedal spasms.
- Total thyroidectomy removes the source of calcitonin, making an **excess** highly unlikely as a cause for postoperative hypocalcemia.
*Inadequate calcium dosing requiring higher infusion rate*
- Although the patient has severe hypocalcemia, the lack of response to **IV calcium gluconate** is a hallmark of an underlying metabolic block.
- Simply increasing the dose will not address the **PTH resistance** caused by the patient's low magnesium levels.
*Pseudohypoparathyroidism from PTH receptor mutation*
- **Pseudohypoparathyroidism** is a congenital condition characterized by end-organ resistance to PTH, typically presenting with **elevated** PTH levels.
- This patient's low PTH and recent surgical history point to **iatrogenic** or metabolic causes rather than a genetic receptor mutation.
Question 5: A 70-year-old man with type 2 diabetes, hypertension, and stage 4 CKD (eGFR 25 mL/min/1.73m²) presents with HbA1c of 9.2%. Current medications include metformin 1000 mg twice daily, lisinopril, and atorvastatin. He experienced severe hypoglycemia twice in the past month with glucose readings in the 40s mg/dL. Analyze the most likely cause of his hypoglycemia.
A. Decreased renal clearance of metformin
B. Reduced renal insulin clearance in advanced CKD (Correct Answer)
C. Insulin secretagogue use not mentioned in history
D. Concurrent cortisol deficiency
E. Progression of diabetic nephropathy causing decreased gluconeogenesis
Explanation: ***Reduced renal insulin clearance in advanced CKD***
- In **advanced CKD** (Stage 4, eGFR < 30 mL/min), the **kidneys' ability to degrade insulin** is significantly diminished, leading to its accumulation in the systemic circulation.
- This prolongation of **endogenous insulin half-life**, combined with impaired **renal gluconeogenesis**, often leads to spontaneous or severe hypoglycemia in diabetic patients.
*Insulin secretagogue use not mentioned in history*
- While **sulfonylureas** or **meglitinides** are common culprits of hypoglycemia in renal failure, they are not listed in the patient's current medication profile.
- It is inaccurate to assume the use of a drug that is explicitly absent from the clinical vignette as the primary cause.
*Decreased renal clearance of metformin*
- Although **metformin** accumulates in patients with an **eGFR < 30**, its primary toxicity is **lactic acidosis**, not direct stimulation of insulin release.
- Metformin does not typically cause **hypoglycemia** as a monotherapy because it does not increase pancreatic insulin secretion.
*Progression of diabetic nephropathy causing decreased gluconeogenesis*
- While the failing kidney does lose its capacity for **gluconeogenesis**, the primary driver of spontaneous hypoglycemia in CKD is typically the **reduced clearance of insulin**.
- Decreased gluconeogenesis is a contributing factor, but it is less clinically significant than the **hormonal accumulation** occurring in Stage 4-5 CKD.
*Concurrent cortisol deficiency*
- **Adrenal insufficiency** can cause hypoglycemia, but it would typically present with other signs such as **hyperkalemia**, **hyponatremia**, or hypotension.
- There is no clinical suggestion of **Addison's disease** or pituitary failure in this patient to prioritize this over clear **renal dysfunction**.
Question 6: A 38-year-old woman presents with fatigue, weight gain, and cold intolerance. Labs show TSH 45 mIU/L, free T4 0.4 ng/dL, and positive anti-thyroid peroxidase antibodies. She is started on levothyroxine 100 mcg daily. Four weeks later, she reports palpitations, anxiety, and insomnia. Repeat TSH is 35 mIU/L and free T4 is 2.5 ng/dL. What best explains these findings?
A. Concurrent Graves disease development
B. Poor medication adherence followed by excessive dosing (Correct Answer)
C. Thyroid hormone resistance syndrome
D. Laboratory error requiring repeat testing
E. TSH-secreting pituitary adenoma
Explanation: ***Poor medication adherence followed by excessive dosing***
- The patient's elevated **Free T4** indicates recent high intake of **levothyroxine**, but the **TSH** remains high because it is a **lagging indicator** that takes 6–8 weeks to normalize.
- This pattern is classic for a patient who missed doses and then took **multiple tablets** shortly before the blood test to overcompensate, causing transient **exogenous thyrotoxicosis**.
*Thyroid hormone resistance syndrome*
- While this syndrome presents with elevated T4 and inappropriately high TSH, it is a **congenital condition** and would not present with a high TSH of 45 at baseline followed by thyrotoxic symptoms after starting meds.
- Patients with **Resistance to Thyroid Hormone (RTH)** are typically **clinically euthyroid** or hypothyroid, not symptomatic with palpitations from replacement dose changes.
*Concurrent Graves disease development*
- **Graves disease** would cause a suppressed TSH (near zero), whereas this patient has a significantly elevated **TSH of 35 mIU/L**.
- The presence of **Anti-TPO antibodies** confirms **Hashimoto thyroiditis**, and while the two can rarely coexist, the lab pattern here is better explained by dosing kinetics.
*TSH-secreting pituitary adenoma*
- A **TSHoma** would present with high T4 and high TSH, but it usually presents with **visual field defects** or permanent hyperthyroid symptoms, not as a response to starting levothyroxine.
- This diagnosis is extremely rare compared to **medication non-adherence**, and would not explain the initial hypothyroid state presenting with a TSH of 45.
*Laboratory error requiring repeat testing*
- While laboratory errors occur, this specific pattern of **elevated Free T4** and **elevated TSH** is a well-recognized clinical phenomenon related to **medication kinetics**.
- Clinical symptoms of **palpitations and anxiety** correlate with the high Free T4 level, making an error less likely than physiological reality.
Question 7: A 55-year-old man with type 2 diabetes presents to the emergency department with confusion and lethargy. His glucose is 750 mg/dL, sodium 155 mEq/L, serum osmolality 380 mOsm/kg, pH 7.38, and bicarbonate 24 mEq/L. Urine ketones are negative. He is started on IV fluids and insulin. Six hours later, his glucose is 250 mg/dL but he remains confused. What is the most appropriate next step?
A. Continue current management and recheck glucose
B. Stop insulin and start subcutaneous regimen
C. Increase insulin infusion rate
D. Order head CT to evaluate for stroke
E. Add dextrose to IV fluids and continue insulin (Correct Answer)
Explanation: ***Add dextrose to IV fluids and continue insulin***
- In **Hyperosmolar Hyperglycemic State (HHS)**, when blood glucose reaches **250-300 mg/dL**, dextrose must be added to IV fluids to allow for the continued administration of insulin to normalize **osmolality** and **mental status** without causing hypoglycemia.
- The continued confusion despite a drop in glucose is common in HHS as **hyperosmolality** takes longer to resolve than hyperglycemia; adding dextrose ensures the **insulin infusion** can be maintained safely.
*Increase insulin infusion rate*
- Increasing the insulin rate when glucose is already down to 250 mg/dL would pose a severe risk of **hypoglycemia** and a rapid shift in osmotic pressure.
- The goal at this stage is to slow the rate of glucose decline to avoid **cerebral edema** while focusing on correcting the fluid deficit.
*Continue current management and recheck glucose*
- Simply continuing current management without adding glucose once levels are at 250 mg/dL will likely lead to **hypoglycemia** because the insulin infusion is still active.
- Management must be dynamic; the standard of care for HHS requires shifting to **dextrose-containing fluids** at this specific glucose threshold.
*Stop insulin and start subcutaneous regimen*
- Insulin should not be transitioned to a subcutaneous regimen until the patient is **mentally alert**, able to eat, and the **serum osmolality** has significantly improved.
- Prematurely stopping the IV insulin infusion can lead to a rebound in **hyperglycemia** and delay the resolution of the hyperosmolar state.
*Order head CT to evaluate for stroke*
- While stroke is a differential for confusion, metabolic causes (high **serum osmolality** of 380 mOsm/kg) are the primary explanation for this patient's lethargy.
- **Neurological improvement** in HHS often lags behind glucose correction by several hours, so immediate imaging is not indicated unless there are focal neurological deficits.
Question 8: A 28-year-old pregnant woman at 10 weeks gestation presents with fatigue, palpitations, and tremor. TSH is <0.01 mIU/L, free T4 is 3.2 ng/dL, and β-hCG is markedly elevated at 400,000 mIU/mL. Thyroid stimulating immunoglobulins are negative. Ultrasound shows a molar pregnancy. What is the most appropriate management of her thyroid condition?
A. Start propylthiouracil immediately
B. Radioactive iodine therapy
C. Start methimazole immediately
D. Emergency thyroidectomy
E. Uterine evacuation and supportive care (Correct Answer)
Explanation: ***Uterine evacuation and supportive care***
- The patient has **gestational hyperthyroidism** caused by extremely high levels of **hCG**, which shares a common **alpha-subunit** with TSH and acts as a weak TSH receptor agonist.
- The primary treatment is **surgical evacuation** of the molar pregnancy, which rapidly reduces hCG levels and typically resolves the thyrotoxicosis without the need for long-term antithyroid drugs.
*Start methimazole immediately*
- **Methimazole** is generally avoided in the **first trimester** due to potential **teratogenicity**, such as aplasia cutis and choanal atresia.
- Antithyroid drugs are not the definitive treatment for hyperthyroidism secondary to **hydatidiform mole**, as the condition is self-limiting once the mole is removed.
*Start propylthiouracil immediately*
- While **Propylthiouracil (PTU)** is the preferred thionamide in the first trimester, it is not the primary treatment for **hCG-induced hyperthyroidism**.
- Use of PTU carries risks of **hepatotoxicity** and is unnecessary when the stimulus (hCG) can be removed surgically.
*Radioactive iodine therapy*
- **Radioactive iodine** is absolutely **contraindicated in pregnancy** because it crosses the placenta and can cause permanent **neonatal hypothyroidism**.
- It is used for autoimmune or autonomous thyroid disease, not for transient hyperthyroidism associated with **trophoblastic disease**.
*Emergency thyroidectomy*
- **Thyroidectomy** is an invasive procedure that is not indicated for **hCG-mediated thyrotoxicosis**, which is expected to resolve following uterine evacuation.
- Surgery carries significant risks and is reserved for cases where medical therapy fails or **malignancy** is suspected in the native thyroid gland.
Question 9: A 62-year-old man with type 2 diabetes mellitus on metformin and glipizide presents for routine follow-up. His HbA1c is 8.5% (goal <7%). He has a history of heart failure with reduced ejection fraction (EF 35%) and chronic kidney disease stage 3 (eGFR 45 mL/min/1.73m²). Which medication should be added to improve both glycemic control and cardiovascular outcomes?
A. Pioglitazone
B. Sitagliptin
C. Insulin glargine
D. NPH insulin
E. Empagliflozin (Correct Answer)
Explanation: ***Empagliflozin***
- **SGLT2 inhibitors** like empagliflozin are the drug of choice for patients with **Heart Failure with reduced Ejection Fraction (HFrEF)** as they significantly reduce heart failure hospitalizations and cardiovascular mortality.
- In patients with **Chronic Kidney Disease (CKD)**, these agents provide **renoprotection** by reducing intraglomerular pressure and slowing the progression of renal decline.
*Insulin glargine*
- While effective for reaching **HbA1c goals**, basal insulin is associated with **weight gain** and a higher risk of **hypoglycemia**.
- It does not offer the specific **cardiovascular or renal survival benefits** provided by SGLT2 inhibitors in the setting of heart failure.
*Pioglitazone*
- **Thiazolidinediones** are strictly **contraindicated** in patients with heart failure because they promote **fluid retention** and peripheral edema.
- Use of this medication in a patient with an **EF of 35%** could lead to an acute exacerbation of congestive heart failure.
*Sitagliptin*
- **DPP-4 inhibitors** are generally **weight-neutral** and safe in CKD with dose adjustments, but they offer no proven **cardiovascular benefit**.
- Specifically, some members of this class (like saxagliptin) are associated with an **increased risk of hospitalization** for heart failure.
*NPH insulin*
- NPH is an intermediate-acting insulin that carries a significant risk of **nocturnal hypoglycemia** compared to long-acting analogs.
- Like other insulin formulations, it provides **no outcome-modifying benefits** for a patient's underlying heart failure or chronic kidney disease.
Question 10: A 45-year-old woman presents with heat intolerance, palpitations, and a 15-pound weight loss over 3 months. Physical examination reveals a diffusely enlarged, non-tender thyroid gland, fine tremor, and exophthalmos. TSH is 0.01 mIU/L (normal: 0.4-4.0), free T4 is 3.8 ng/dL (normal: 0.8-1.8), and thyroid-stimulating immunoglobulin is elevated. What is the most appropriate initial management?
A. Propylthiouracil alone
B. Thyroidectomy within 1 week
C. Methimazole and propranolol (Correct Answer)
D. Levothyroxine replacement
E. Radioactive iodine ablation immediately
Explanation: ***Methimazole and propranolol***
- **Methimazole** is the preferred **thionamide** for initial management of **Graves' disease** (confirmed by **TSI** and **exophthalmos**) as it inhibits **thyroid peroxidase** with a lower risk of hepatotoxicity than alternatives.
- **Propranolol** is indicated for rapid control of **sympathetic symptoms** such as palpitations, tremors, and heat intolerance by blocking beta-adrenergic receptors.
*Propylthiouracil alone*
- PTU is primarily reserved for the **first trimester of pregnancy** or **thyroid storm** due to the associated risk of **severe liver failure**.
- Using it alone without a **beta-blocker** would fail to provide immediate relief for the patient's symptomatic tachycardia and tremors.
*Radioactive iodine ablation immediately*
- This definitive treatment can acutely **worsen exophthalmos** due to the release of thyroid antigens and should not be used as the very first step before medical stabilization.
- Patients are typically pre-treated with **thionamides** to achieve a euthyroid state to prevent a spike in thyroid hormone levels during treatment.
*Thyroidectomy within 1 week*
- Surgery is generally reserved for patients with **compressive symptoms**, large goiters, or suspected malignancy rather than as a standard initial step.
- Operating on a severely hyperthyroid patient without first achieving a **euthyroid state** poses a significant risk of inducing a life-threatening **thyroid storm**.
*Levothyroxine replacement*
- Levothyroxine is a synthetic form of T4 used to treat **hypothyroidism**, which would be contraindicated and dangerous given this patient's already elevated **Free T4**.
- Administering this medication would exacerbate the patient's **thyrotoxicosis** and increase the risk of cardiac arrhythmias.
